Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
3rd COVID-19 vaccine dose in cancer patients on chemotherapy
NCT04936997Phase 1Completed
- Sponsor
- University of Arizona
- Start
- Jun 2021
- Primary completion
- Aug 2021
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of tozinameran in coronavirus disease 2019 (COVID-19), sponsored by University of Arizona. Primary endpoint: Immune response at 3 months. Started Jun 2021; status: completed.
02
Drugs
tozinameran
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04936997.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04936997.